drugset / Trial / NCT06397001
Treatment of AA Amyloidosis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and efficacy of a subcutaneous injection of nL-SAA1-01in a patient with AA Amyloidosis.
Timeline
- Start
- 2023-11-28
- Primary completion
- 2024-12-02
- Completion
- 2024-12-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | nL-SAA1-01 | Antisense oligonucleotide | — | Subcutaneous |